Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07076485

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Led by M.D. Anderson Cancer Center · Updated on 2026-04-15

768

Participants Needed

3

Research Sites

280 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.

CONDITIONS

Official Title

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed invasive breast cancer
  • Recommended for regional nodal irradiation by a radiation oncologist
  • Negative final surgical margins
  • No more than 12 weeks since final breast/lymph node surgery or chemotherapy
  • Age 18 years or older
  • Prior or concurrent malignancy allowed if it does not interfere with study assessments
  • Ability and willingness to provide informed consent
  • May be enrolled in other non-conflicting studies
  • For low-risk lumpectomy cohort: pathologic or clinical stage appropriate, treated with lumpectomy or axillary surgery only, no nodal boost recommended
  • For high-risk lumpectomy cohort: treated with neoadjuvant chemotherapy, clinical stage cT0-T4b N1-N3a/b/c, treated with lumpectomy or axillary surgery only, nodal boost recommended
  • For low-risk mastectomy cohort: pathologic or clinical stage appropriate, residual tumor cellularity ≤ 20% if neoadjuvant chemotherapy, treated with mastectomy, surgical margins ≥ 2 mm, no or focal lymphovascular invasion, age 40 years or older, no chest wall boost recommended
  • For high-risk mastectomy cohort: appropriate pathologic or clinical stage, treated with mastectomy, chest wall and/or nodal boost recommended
  • Women of child-bearing potential and men must agree to use adequate contraception during radiation treatment
  • Women not required to have pregnancy test at enrollment but must comply with pregnancy assessment policy
Not Eligible

You will not qualify if you...

  • Prior therapeutic radiation overlapping the breast or nodal areas needing radiation
  • History of scleroderma
  • Pregnant women
  • Psychiatric illness or social situations limiting study compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Cooper Hospital University Medical Center

Voorhees Township, New Jersey, United States, 08103

Actively Recruiting

2

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

3

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States, 78229

Actively Recruiting

Loading map...

Research Team

B

Benjamin Smith, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

8

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here